Acorda Therapeutics, Inc. (ACOR)
Company Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.
It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure.
In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
The company was incorporated in 1995 and is headquartered in Pearl River, New York.
| Country | United States |
| Founded | 1995 |
| IPO Date | Feb 10, 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Dr. Ron Cohen M.D. |
Contact Details
Address: Two Blue Hill Plaza Pearl River, New York 10965 United States | |
| Phone | 914-347-4300 |
| Website | acorda.com |
Stock Details
| Ticker Symbol | ACOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001008848 |
| CUSIP Number | 00484M106 |
| ISIN Number | US00484M7002 |
| Employer ID | 13-3831168 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ron Cohen M.D. | Founder, Chief Executive Officer, President and Director |
| Dr. Burkhard Blank M.D. | Interim Head of Drug Safety |
| Michael A. Gesser M.B.A. | Chief Financial Officer |
| Robert Morales | Interim Principal Accounting Officer, Principal Financial Officer, Vice President of Finance and Controller |
| Felicia Vonella | Vice President of Investor Relations |
| Neil S. Belloff Esq. | General Counsel and Corporate Secretary |
| Tierney Saccavino | Executive Vice President of Corporate Communications |
| Denise J. Duca | Executive Vice President of Human Resources |
| Andrew Mayer J.D. | Senior Vice President |
| Kerry M. Clem | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 1, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Aug 9, 2023 | 10-Q | Quarterly Report |
| Aug 8, 2023 | 8-K | Current Report |
| Jun 27, 2023 | 8-K | Current Report |
| Jun 26, 2023 | 8-K | Current Report |
| Jun 2, 2023 | 8-K | Current Report |
| Jun 1, 2023 | 8-K | Current Report |
| May 31, 2023 | 8-K | Current Report |